Case | GA (days or weeks) | Treatment initiation time | Regimen | Outcomes (pregnancy outcome, complications or side effects) |
Delgado & Davenport28 (2012) | ||||
1 | 8 weeks | 30–40 hours | 200 mg in oil, IM, daily x 2 days; then two doses every other day x 2; then twice weekly until 9 weeks 5 days; then restarted at 11 weeks 2 days, twice weekly; then decreased to 100 mg twice weekly until 29 weeks 5 days | Viable infant at 37 weeks |
2 | 11 weeks | 72 hours | 200 mg in oil, IM; continued for 2 weeks (unknown frequency); then PO micronised progesterone for 5 months (unknown frequency and dosage) | Viable infant |
3 | 7 weeks | 36–48 hours | 200 mg in oil, IM; then two more times the first week, then weekly for 5–6 weeks, then 200 mg in oil twice weekly for 2 weeks, then micronised progesterone orally for 5 months | Viable infant at 39 weeks |
4 | 7 weeks 4 days | 46 hours | 200 mg in oil, IM, twice weekly for 19 weeks | Viable infant at 40 weeks |
5 | Unknown | Unknown | 200 mg in oil, route and frequency unknown | Abortion soon after injection |
6 | 7 weeks | 7 hours | 200 mg PV; followed by IM 200 mg after 11 hours; then 2 days later | Abortion complete 3 days after mifepristone |
7 | Lost to follow-up; no information available | |||
Garratt & Turner30 (2107) | ||||
N | 43 days | 28 hours | Vaginal progesterone: 400 mg twice daily for 3 days, then 400 mg nightly for 6 days, then 200 mg nightly for 6 days; routine antenatal care after 2 weeks of progesterone | Viable pregnancy at 8 weeks 4 days on ultrasound at 2 weeks; viable infant at 39 weeks |
T | 61 days | 3.5 hours | Same as above | LTFU at 2-week follow-up ultrasound; reported delivery of live infant “7 months later, likely at term” |
O | 7.5 weeks | 31 hours | One dose of vaginal progesterone 400 mg; discontinued as experienced heavy vaginal bleeding soon after treatment initiation | Heavy vaginal bleeding soon after starting progesterone; follow-up US at 1 week showed empty uterus, completed abortion |
Delgado et al 29 | ||||
N/A | 754 treated 5 weeks: 19 6 weeks: 113 7 weeks: 102 8 weeks: 88 9 weeks: 30 Unknown: 138 | Variable (72 hours or less) | High-dose oral progesterone: 31 IM progesterone: 125 Oral, all groups: 119* Vaginal caps: 156 Vaginal suppository: 34 Unknown: 82 | Outcomes available for 547: Births: 257 LTFU before 20 weeks: 112 LTFU after 20 weeks: 4 Excluded because chose to complete abortion: 57 Excluded because wrong time interval: 38 Ongoing pregnancies by progesterone regimen: High-dose oral: 21/31 (68%) IM progesterone all groups: 80/125 (64%) Oral, all groups: 64/119 (54%) Vaginal caps: 61/156 (39%) Vaginal suppository: 11/34 (32%) Ongoing pregnancies by gestational age: 5 weeks: 19/76 (25%) 6 weeks: 61/113 (46%) 7 weeks: 50/102 (49%) 8 weeks: 54/88 (61%) 9 weeks: 23/30 (77%) Birth defects: 6 (2 absent digits; 1 choroid plexus cyst, 1 cystic kidney, 1 failed hearing test, 1 heart murmur) |
Creinin et al 31 (2020) | ||||
1 | 53 days | 24 hours | Mifepristone 200 mg, followed by oral progesterone 400 mg 24 hours later - twice daily for 3 days, then once daily until planned surgical abortion 14–16 days after enrollment | Continuing GCA at 17 days |
2 | 50 days | 24 hours | Same as above | Continuing GCA at 16 days |
5 | 49 days | 24 hours | Same as above | Continuing GCA at 16 days |
8 | 56 days | 24 hours | Same as above | Expelled pregnancy, haemorrhage not requiring transfusion or uterine aspiration at day 3 |
9 | 47 days | 24 hours | Same as above | Nausea, vomiting, dehydration; requested aspiration at day 3 |
12 | 48 days | 24 hours | Same as above | Continuing GCA at 15 days |
3 | 50 days | 24 hours | Placebo | Continuing GCA at 16 days |
4 | 48 days | 24 hours | Placebo | No GCA at 4 days |
6 | 61 days | 24 hours | Placebo | Continuing GCA at 16 days |
7 | 48 days | 24 hours | Placebo | D&C requested (bleeding, anxiety) at day 4 |
10 | 60 days | 24 hours | Placebo | Expelled pregnancy, incomplete, emergent D&C at day 5 |
11 | 60 days | 24 hours | Placebo | Expelled pregnancy, incomplete, emergent D&C, transfusion at day 6 |
*Unclear if this group includes the individuals treated with high-dose oral progesterone.
D&C, dilation and curettage; GA, gestational age; GCA, gestational cardiac activity; IM, intramuscular; LTFU, lost to follow-up; N/A, not available; PO, per os; PV, per vagina; US, ultrasound.